Neurocrine Biosciences, Inc. (NASDAQ:NBIX) insider Haig P. Bozigian sold 1,625 shares of the stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $79.12, for a total transaction of $128,570.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) traded up $2.68 during trading hours on Friday, hitting $78.56. 954,500 shares of the stock traded hands, compared to its average volume of 1,110,858. Neurocrine Biosciences, Inc. has a 12-month low of $38.43 and a 12-month high of $83.84. The company has a debt-to-equity ratio of 1.05, a quick ratio of 14.37 and a current ratio of 14.38. The stock has a market cap of $7,130.00, a PE ratio of -35.39, a price-to-earnings-growth ratio of 70.98 and a beta of 0.35.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its earnings results on Wednesday, November 1st. The company reported ($0.13) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.49) by $0.36. The company had revenue of $60.77 million during the quarter, compared to analysts’ expectations of $29.38 million. During the same period in the prior year, the business posted ($0.43) earnings per share. equities research analysts expect that Neurocrine Biosciences, Inc. will post -1.59 earnings per share for the current fiscal year.

Several large investors have recently bought and sold shares of NBIX. Janus Henderson Group PLC purchased a new stake in shares of Neurocrine Biosciences in the 2nd quarter worth about $246,888,000. HealthCor Management L.P. lifted its position in shares of Neurocrine Biosciences by 108.2% in the 2nd quarter. HealthCor Management L.P. now owns 2,550,178 shares of the company’s stock worth $117,308,000 after purchasing an additional 1,325,178 shares during the period. Perceptive Advisors LLC lifted its position in shares of Neurocrine Biosciences by 33.9% in the 3rd quarter. Perceptive Advisors LLC now owns 4,791,589 shares of the company’s stock worth $293,629,000 after purchasing an additional 1,214,000 shares during the period. FMR LLC lifted its position in shares of Neurocrine Biosciences by 9.8% in the 2nd quarter. FMR LLC now owns 13,211,023 shares of the company’s stock worth $607,707,000 after purchasing an additional 1,180,874 shares during the period. Finally, Goldman Sachs Group Inc. lifted its position in shares of Neurocrine Biosciences by 53.3% in the 2nd quarter. Goldman Sachs Group Inc. now owns 2,674,217 shares of the company’s stock worth $123,014,000 after purchasing an additional 930,268 shares during the period.

Several equities analysts recently commented on the stock. Leerink Swann reaffirmed an “outperform” rating and set a $83.00 target price (up previously from $72.00) on shares of Neurocrine Biosciences in a report on Thursday, November 2nd. Citigroup reissued a “buy” rating and issued a $79.00 price target on shares of Neurocrine Biosciences in a report on Thursday, November 2nd. Barclays raised their price target on shares of Neurocrine Biosciences from $75.00 to $85.00 and gave the stock an “overweight” rating in a report on Thursday, November 2nd. BidaskClub raised shares of Neurocrine Biosciences from a “hold” rating to a “buy” rating in a report on Thursday, January 4th. Finally, BMO Capital Markets raised their price target on shares of Neurocrine Biosciences from $83.00 to $109.00 and gave the stock an “outperform” rating in a report on Thursday, November 2nd. One equities research analyst has rated the stock with a hold rating and eighteen have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $82.31.

TRADEMARK VIOLATION NOTICE: “Neurocrine Biosciences, Inc. (NBIX) Insider Sells $128,570.00 in Stock” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this report on another site, it was stolen and republished in violation of U.S. & international copyright & trademark law. The original version of this report can be read at https://www.thecerbatgem.com/2018/01/19/neurocrine-biosciences-inc-nbix-insider-sells-128570-00-in-stock.html.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.

Insider Buying and Selling by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.